Apyx Medical announces two peer-reviewed studies on Renuvion in body contouring showing safety and efficacy

Apyx Medical Corp

First prospective RCT (Barone, 76 patients) shows Renuvion improves abdominal skin laxity and satisfaction scores vs lipoabdominoplasty alone.
Second retrospective study (Vanek, 77 patients) finds no significant increase in complications with Renuvion despite longer surgical times.
CEO cites >15M patients on GLP-1 drugs as growth driver; Renuvion is only FDA-cleared device for post-liposuction skin laxity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.